Orion Group Holdings reported a 14% increase in Q3 2026 revenue to $256.2 million and net income rose to $5.5 million, or $0.14 per diluted share, driven by strong performance in its Concrete and Marine segments. The company secured $179 million in new awards, including two additional U.S. Navy contracts, supporting its positive outlook. Orion reiterated its full-year 2026 guidance, expecting continued growth and profitability. This reflects robust demand in infrastructure and defense sectors, positioning Orion for sustained shareholder value creation.
Orion Group Holdings' third quarter 2026 results come amid a Industrials sector where 84 of 135 US stocks rose and 51 fell on Pluang. For readers following Industrials, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: LUNR (Intuitive Machines) rose 9.73% to USD 11.50 with 91% sell order activity and a typical hold time of 10 days; AMSC (American Superconductor Corporation) gained 8.90% to USD 27.66 with a typical hold time of 35 days; RKLB (Rocket Lab USA Inc) increased 8.53% to USD 58.41 with 95% sell order activity and a typical hold time of 32 days.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
